BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 28, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2020

View Archived Issues

Novel variant linked to childhood steroid-sensitive nephrotic syndrome

Read More

HanaVax, University of Tokyo present mutated Pneumococcal surface proteins

Read More

New CD73 inhibitors synthesized at Eternity Bioscience

Read More

J2H Biotech, Ahn-Gook Pharmaceutical describe new mirabegron prodrugs

Read More

University of Florida identifies new PRMT5 inhibitors

Read More

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical patent ERK-1/2 inhibitors

Read More

Dimerix announces positive data from phase II ACTION trials of DMX-200 in kidney disease

Read More

Global phase III PolarisDMD trial of edasalonexent does not meet primary endpoint

Read More

XL-092: a promising pan-tyrosine kinase inhibitor in clinical development

Read More

First patient enrolled in the immune modulation domain of REMAP-COVID substudy

Read More

Prilenia initiates enrollment in phase III PROOF-HD trial of pridopidine

Read More

New phase I/Ib study to evaluate GEN-001 with avelumab for solid tumors

Read More

Positive 6-month interim analysis data presented from TOPAZ phase II study of SRK-015

Read More

Alzheon studies ALZ-801 in phase II biomarker study for early Alzheimer's

Read More

UKRI conditionally approves grant funding to explore SDC-1801 as treatment of COVID-19

Read More

SIMR-1281: a novel candidate for clinical trials in cancer

Read More

ASHG 2020: New inflammatory disease, and maybe, a new classification system

Read More

First-in-human data presented for TPX-0022

Read More

FDA clears IND for phase Ib study of bempegaldesleukin for COVID-19

Read More

Spero Therapeutics' SPR-720 shows promise in phase I study

Read More

Voclosporin studied for antiviral effects in kidney transplant recipients with COVID-19

Read More

Apollomics reports phase I data for APL-101

Read More

FDA approves Eysuvis for short-term treatment of dry eye disease

Read More

Valo Therapeutics describes design and preclinical results with neoantigen-coated oncolytic viruses

Read More

Novel selective TRK degraders effectively reduce TPM3-TRKA fusion protein levels

Read More

New pilot study to evaluate afamelanotide for arterial ischemic stroke

Read More

Histogen and Amerimmune collaborate to study emricasan for COVID-19

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 27, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing